ETOPOPHOS® Injection Launch

July 11, 2019|

H2-Pharma, LLC has entered into an agreement with CHEPLAPHARM Arzneimittel GmbH to be the exclusive U.S. distributor of ETOPOPHOS® (etoposide phosphate) for injection...

End-to-End Order Processing

May 4, 2018|

H2-Pharma Automates Order Processing End-to-End—Including Chargeback Processing and Warehouse Order Fulfillment—with TrueCommerce EDI for QuickBooks Premier..

XENICAL® Capsules

January 11, 2018|

H2-Pharma, LLC has re-launched XENICAL® (orlistat) 120 mg Capsules via its newly formed Branded division. This opportunity arose due to the partnership with CHEPLAPHARM Arzneimittel GmbH...

Mayne Pharma, Inc.

December 6, 2016|

H2-Pharma, LLC has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc. In 2015 the combined market for these products was approximately $8.3 million according to IMS Health.

Ready to talk?

Go to Top